selected scholarly activity
-
chapters
- Glioblastoma Stem Cells Drive Tumor Recurrence and Patient Relapse: What's the Evidence?. 193-208. 2014
- Cancer Genomics Brain Tumor Genomics: Sequencing to Clinical Utility. 321-338. 2014
- Chapter 19 Brain Tumor Genomics Sequencing to Clinical Utility. 321-338. 2014
- Brain Tumor Genomics: Sequencing to Clinical Utility. 321-338. 2013
-
conferences
- Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Reports. 111420-111420. 2022
- Abstract PO081: Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma. Cancer immunology research. PO081-PO081. 2021
- Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence. Cancer Research. 570-570. 2019
- Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence. Immunology. 570-570. 2019
- BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. 1702-1716. 2019
- Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies. Cancer Research. 1763-1763. 2018
- Abstract 1911: Uncovering novel targets of recurrent glioblastoma using transcriptomic profiling in a patient-derived xenograft model. Cancer Research. 1911-1911. 2018
- Abstract 390: Genome-wide CRISPR screens in brain tumor initiating cells (BTICs) identify potent sensitizers and resistors of conventional chemoradiotherapy. Cancer Research. 390-390. 2018
- Abstract 44: Characterization and targeting of a temporal micro-metastatic signature in human brain metastases. Cancer Research. 44-44. 2018
- CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 229-229. 2017
- PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 49-49. 2017
- Abstract 3639: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma. Cancer Research. 3639-3639. 2017
- Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma. Cancer Research. 3758-3758. 2017
- Abstract 3844: Identification and validation of novel therapeutic targets driving clonal heterogeneity in treatment-refractory GBM. Cancer Research. 3844-3844. 2017
- Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. Cancer immunology research. B079-B079. 2016
- Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma. Cancer immunology research. B092-B092. 2016
- Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells. Cancer Research. 1481-1481. 2016
- Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors. Cancer Research. 2300-2300. 2016
- Abstract 2512: Bmi1 identifies treatment-refractory stem cells in human glioblastoma. Cancer Research. 2512-2512. 2016
- RM-06 * IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE. Neuro-Oncology. v187-v187. 2014
- SC-33 * POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT. Neuro-Oncology. v204-v204. 2014
- SOX2 IDENTIFIES THE TREATMENT-REFRACTORY STEM CELL POPULATION IN GROUP 2 MEDULLOBLASTOMA. Neuro-Oncology. iii5-iii5. 2014
-
journal articles
- ENHANCING GLIOBLASTOMA TREATMENT: ALLOGENEIC CAR-T CELLS OVERCOMES FUNCTIONAL DEFICITS OF PATIENT-DERIVED AUTOLOGOUS PRODUCTS. Neuro-Oncology. 26. 2024
- Abstract 5241: Generation of allogeneic CAR-T circumvents functional deficits in patient-derived autologous product for glioblastoma. Cancer Research. 84:5241-5241. 2024
- Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases. Clinical Cancer Research. 30:554-563. 2024
- SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA. NOA. 5:iii34-iii34. 2023
- AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA. NOA. 5:i6-i6. 2023
- Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma 2022
- CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. Journal for ImmunoTherapy of Cancer. 10:e003289-e003289. 2022
- Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence. Science Advances. 7:eabi5568. 2021
- EXTH-53. ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER. Neuro-Oncology. 23:vi175-vi175. 2021
- Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma 2021
- Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials. 252:120105-120105. 2020
- The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 26:832-844.e6. 2020
- Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. Frontiers in Immunology. 11:599253. 2020
- Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. Journal of Neuro-Oncology. 143:417-428. 2019
- EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. Methods in molecular biology (Clifton, N.J.). 1869:155-168. 2019
- TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 20:vi273-vi273. 2018
- Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma. Cancer Research. 78:5023-5037. 2018
- Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis. Cancer Research. 78:5124-5134. 2018
- Identification and Co-Targeting of EphA2/EphA3 Cancer Stem Cells in Recurrent Human Glioblastoma. SSRN Electronic Journal. 2018
- RNAi screen identifies essential regulators of human brain metastasis-initiating cells. Acta Neuropathologica. 134:923-940. 2017
- CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi46-vi46. 2017
- CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi49-vi49. 2017
- CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 19:vi54-vi54. 2017
- IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 19:vi113-vi113. 2017
- STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 19:vi229-vi229. 2017
- STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi234-vi235. 2017
- TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19:vi254-vi254. 2017
- TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi255-vi255. 2017
- Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Annals of Oncology. 28:1448-1456. 2017
- pERK1/2 Peripheral Recruitment and Filopodia Protrusion Augment Oligodendrocyte Progenitor Cell Migration: Combined Effects of PDGF-A and Fibronectin. Cellular and Molecular Neurobiology. 37:183-194. 2017
- IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. Neuro-Oncology. 18:vi98-vi98. 2016
- TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma. Neuro-Oncology. 18:vi207-vi207. 2016
- TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS. Neuro-Oncology. 18:vi211-vi212. 2016
- Modelling Therapy Resistance for the Identification of Treatment-Refractory Cell Population(s) in Human Glioblastoma. Canadian Journal of Neurological Sciences. 43:S1-S1. 2016
- OS2 - 166 A Novel Model of Human Lung-to-Brain Metastasis and its Application to the Identification of Essential Metastatic Regulatory Genes. Canadian Journal of Neurological Sciences. 43:S2-S2. 2016
- PS1 - 169 Discovering the Treatment Refractory BTIC Population in Group 3 Medulloblastoma through Therapy Adapted Patient-Derived Human Mouse Xenograft (PDX) Model. Canadian Journal of Neurological Sciences. 43:S10-S10. 2016
- PS1 - 170 Bmi1 is a Therapeutic Target in Recurrent Childhood Medulloblastoma. Canadian Journal of Neurological Sciences. 43:S10-S10. 2016
- PS2 - 171 Bmi1 Identifies Treatment-Refractory Stem Cells in Human Glioblastoma. Canadian Journal of Neurological Sciences. 43:S13-S13. 2016
- PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells. Canadian Journal of Neurological Sciences. 43:S13-S14. 2016
- A novel stem cell culture model of recurrent glioblastoma. Journal of Neuro-Oncology. 126:57-67. 2016
- Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells. Clinical Cancer Research. 21:5324-5337. 2015
- ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 17:v38.4-v39. 2015
- STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 17:v213.1-v213. 2015
- STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. 6:27461-27477. 2015
- Culture and Isolation of Brain Tumor Initiating Cells. Current Protocols in Stem Cell Biology. 34:3.3.1-3.3.13. 2015
- Revealed: The spy who regulates neuroblastoma stem cells. Oncotarget. 5:11014-11016. 2014
- Generation of Murine Xenograft Models of Brain Tumors from Primary Human Tissue for In Vivo Analysis of the Brain Tumor-Initiating Cell. Methods in molecular biology (Clifton, N.J.). 1210:37-49. 2014
- CXCL1 regulation of oligodendrocyte progenitor cell migration is independent of calcium signaling. Experimental Neurology. 236:259-267. 2012
- The role of dorsal root ganglia activation and brain‐derived neurotrophic factor in multiple sclerosis. Journal of Cellular and Molecular Medicine. 16:1856-1865. 2012
- Differential effects of growth factors on oligodendrocyte progenitor migration. European Journal of Cell Biology. 90:649-656. 2011
- A novel transcriptional regulator of myelin gene expression: implications for neurodevelopmental disorders. NeuroReport. 21:917-921. 2010
- The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding. Biochemical Journal. 404:131-140. 2007